Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.37 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | LCK | P06239 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.32 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4933053 | 0.88 | ESR1 (0.41) | ESR1ESR2HIF1AEGFRPDGFRB | |
| SCHEMBL4934931 | 0.86 | GPBAR1 (0.38) | ESR1ESR2GPBAR1HIF1AEGFR | |
| SCHEMBL4931049 | 0.73 | ESR1 (0.48) | ESR1ESR2HIF1AMAPTBRD4 | |
| SCHEMBL4928663 | 0.73 | MAPT (0.45) | ESR1ESR2HIF1AMAPTTUBB3 | |
| SCHEMBL4931003 | 0.70 | ESR1 (0.44) | ESR1ESR2HIF1AMAPTKAT6A | |
| SCHEMBL4931971 | 0.69 | ALDH1A1 (0.45) | ESR1ESR2HIF1AMAPTKAT6A | |
| SCHEMBL4925484 | 0.69 | KDM4E (0.48) | ESR1ESR2HIF1ALCKMAPT | |
| SCHEMBL4936083 | 0.68 | SMN1; SMN2 (0.52) | ESR1ESR2HIF1AMAPTTP53 | |
| SCHEMBL4935662 | 0.68 | HIF1A (0.47) | ESR1ESR2HIF1AMAPTTP53 | |
| SCHEMBL30292801 | 0.67 | NPC1 (0.54) | ESR1ESR2HIF1AMAPTBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070960-A1 | Novel 3-Aryl-1,2-Benzisoxazole Derivatives and Use Thereof as Medicinal Products Against Cancer | AVENTIS PHARMA S.A. (FR) | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070960-A1 | Novel 3-Aryl-1,2-Benzisoxazole Derivatives and Use Thereof as Medicinal Products Against Cancer | UGT2B7, UGT2B17, CYP4X1 | ESR1 2306/4885ESR2 987/4885GPBAR1 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.